Reinstatement to Quotation
Filed with ASX · · 1 page · English
Summary by 6ix AI
Immutep Ltd has announced the reinstatement of its securities to quotation on the Australian Stock Exchange.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Immutep
- Suspension from Quotation
- Trading Halt
- Half Yearly Report and Accounts
- Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC
- Immutep Achieves 50% Enrolment in Global TACTI-004-1L NSCLC
Later from Immutep
- TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis
- Update on Phase I Study of IMP761 for Autoimmune Diseases
- Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases
- Immutep receives FDA ODD for Efti in Soft Tissue Sarcoma
- Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep